Updated on 2025/04/09

写真a

 
Saiki Masafumi
 
Organization
Graduate Faculty of Interdisciplinary Research Faculty of Medicine Clinical Medicine (Respiratory Medicine) Assistant Professor
Title
Assistant Professor

Degree

  • 学士（医学） ( 山梨大学 )

Papers

  • Endobronchial Aspergilloma.

    So Shimamura, Nozomu Takahashi, Kenta Homma, Tsukasa Satoh, Satoshi Furuya, Hiroki Ohkoshi, Yuki Hoshino, Yoshinori Uchida, Masafumi Saiki, Shinnosuke Ikemura, Kenzo Soejima

    Respirology case reports   13 ( 2 )   e70121   2025.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Bronchial aspergilloma, an uncommon subtype of pulmonary aspergilloma, likely developed in the main bronchus due to airflow stagnation and dryness following lobectomy. Detailed imaging and bronchoscopy provided valuable diagnostic insights, underscoring the importance of considering fungal infections in surgically altered airways.

    DOI： 10.1002/rcr2.70121

    PubMed

  • Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.

    Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, Yosuke Kawashima, Tomohiro Oba, Ryosuke Tsugitomi, Junji Koyama, Yuichi Tambo, Shinsuke Ogusu, Masafumi Saiki, Hiroshi Gyotoku, Tsukasa Hasegawa, Eisaku Miyauchi, Tomoaki Sonoda, Ryota Saito, Katsumi Nakatomi, Toshio Sakatani, Keita Kudo, Yuko Tsuchiya-Kawano, Makoto Nishio

    European journal of cancer (Oxford, England : 1990)   213   115117 - 115117   2024.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Immune checkpoint inhibitors (ICIs) plus chemotherapy is now a standard treatment for non-small cell lung cancer (NSCLC). Whether ICI plus chemotherapy (ICI-chemo) or ipilimumab plus nivolumab (I-N)-based therapy is superior for patients with NSCLC with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1-49 % has not been evaluated. METHODS: This multicenter retrospective study included NSCLC patients with a TPS score of 1-49 %, who began first-line chemotherapy. Propensity score matching analysis was used to adjust for various confounders and evaluate treatment efficacy. RESULTS: A total of 401 patients were enrolled, of whom 308 received ICI-chemo and 93 received I-N-based therapy. The median OS was 21.0 months in the ICI-chemo group and 20.0 months in the I-N-based therapy group. After propensity score matching, there was no difference in OS or PFS between the ICI-chemo group and the I-N-based therapy group (OS: hazard ratios (HR), 0.83; 95 % confidence interval [CI], 0.54-1.26, PFS: HR, 0.72; 95 % CI, 0.52-1.00). Among PD-L1 TPS 25-49 %, there was a tendency for OS to be favorable for the ICI-chemo group (OS: HR, 0.30; 95 % CI, 0.09-0.85). Treatment discontinuation occurred for 26.2 % of the patients in the ICI-chemo group and 41.9 % in the I-N-based therapy group. CONCLUSIONS: Among PD-L1 TPS 1-49 %, there was no significant difference in survival outcomes between the ICI-chemo group and the I-N-based therapy group. Based on the results of a subgroup analysis, ICI-chemo may be superior for treating NSCLC with a TPS of 25-49 %.

    DOI： 10.1016/j.ejca.2024.115117

    PubMed

  • A case of organizing pneumonia in rearranged during transfection fusion-positive lung adenocarcinoma treated with selpercatinib.

    Hiroki Ohkoshi, Masafumi Saiki, Nozomu Takahashi, Kenta Homma, Satoshi Furuya, So Shimamura, Chisa Omori, Yuki Hoshino, Yoshinori Uchida, Shinnosuke Ikemura, Kenzo Soejima

    Thoracic cancer   2024.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Selpercatinib is the first targeted therapy for rearranged during transfection (RET) fusion-positive unresectable non-small-cell lung cancer (NSCLC). The main adverse effects of selpercatinib include hypertension, liver dysfunction, diarrhea, and QT prolongation on electrocardiograms. However, instances of drug-induced interstitial lung disease (DI-ILD) are infrequently reported. We describe the first case of a patient with RET fusion-positive NSCLC treated with selpercatinib who developed DI-ILD, confirmed pathologically. The patient, a 72-year-old woman, initiated selpercatinib treatment following the postoperative recurrence of lung adenocarcinoma. After 15 months of treatment, computed tomography scans revealed multiple infiltrates and ground-glass opacities in both lungs. A thoracoscopic lung biopsy identified organizing pneumonia, attributed to DI-ILD caused by selpercatinib. Although she was asymptomatic, the patient's selpercatinib treatment was discontinued, leading to a gradual improvement in the lung infiltrates. Despite the lack of detailed reports, DI-ILD with selpercatinib represents a potentially serious adverse event and should be approached with caution.

    DOI： 10.1111/1759-7714.15412

    PubMed

  • スタチン内服療法が奏功した肺胞蛋白症の1例

    高橋 望, 島村 壮, 篠原 健, 森川 穂奈美, 大森 千咲, 大越 広貴, 星野 佑貴, 内田 賢典, 齊木 雅史, 池村 辰之介, 大石 直輝, 近藤 哲夫, 副島 研造

    日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集   185回・258回   11 - 11   2024.2

    　More details

    Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

  • A case of autoimmune pulmonary alveolar proteinosis responding to oral statin therapy.

    So Shimamura, Honami Morikawa, Ken Shinohara, Hiroki Ohkoshi, Chisa Omori, Yuuki Hoshino, Yoshinori Uchida, Saiki Masafumi, Shinnosuke Ikemura, Naoki Ohishi, Tetsuo Kondo, Kenzo Soejima

    Respiratory medicine case reports   50   102042 - 102042   2024

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    There is no approved drug treatment for autoimmune pulmonary alveolar proteinosis (APAP), although traditionally requires complex treatments such as whole lung lavage (WLL). We herein report on a 67-year-old man diagnosed with APAP. Treatment with atorvastatin (5 mg daily) resulted in significant improvement in symptoms, lung function, and computed tomography findings, with enhanced oxygenation, although serum anti-GM-CSF antibody levels remained elevated. This case suggests that the remission observed in this case could potentially be attributed to a direct effect of atorvastatin within the pulmonary alveoli. Statins may be considered as one of the treatment options for APAP.

    DOI： 10.1016/j.rmcr.2024.102042

    PubMed

  • The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report Reviewed

    Masafumi Saiki 1, Chisa Omori 1, Honami Morikawa 1, Ken Shinohara 1, So Shimamura 1, Hiroki Ohkoshi 1, Yoshinori Uchida 1, Tomohiro Inoue 2, Tetsuo Kondo 2, Shinnosuke Ikemura 1, Kenzo Soejima

    JTO clinical and research reports   2023.12

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02) Reviewed

    2023.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01) Reviewed

    Thoracic Cancer   2023.1( ISSN：1759-7706 )

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • A case of non-neutropenic invasive pulmonary aspergillosis under immune checkpoint inhibitor therapy for malignant melanoma Reviewed

    Respiratory Medicine Case Reports   2022.3( ISSN：2213-0071 )

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 3期非小細胞肺癌に対する化学放射線治療のICI維持療法中に筋炎を生じ、2年後に重症筋無力症を発症した一例

    古谷 智, 猪股 紀江, 大森 千咲, 渡邉 博, 内田 賢典, 齊木 雅史, 石原 裕

    日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集   181回・248回   36 - 36   2022.2

    　More details

    Language：Japanese   Publisher：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

  • A case of non-neutropenic invasive pulmonary aspergillosis under immune checkpoint inhibitor therapy for malignant melanoma.

    Yoshinori Uchida, So Shimamura, Shuichiro Ide, Kazuki Masuda, Masafumi Saiki, Yusuke Sogami, Hiroshi Ishihara

    Respiratory medicine case reports   37   101627 - 101627   2022

    　More details

    Language：English  

    The patient was a 70-year-old man with diabetes mellitus, alcoholic liver disease and bronchial asthma treated with corticosteroid and long-acting β-agonist inhalants. He had also been treated with nivolumab for advanced malignant melanoma for two years with a partial response. He presented to our department with intractable cough, which was attributed to uncontrolled bronchial asthma. Two weeks later, he presented with a high fever and worsened cough. He was diagnosed with bacterial pneumonia based on severe inflammation revealed by laboratory tests and right upper lung consolidation on chest radiography. Antibiotics via either oral or parenteral administration were ineffective and no pathogen was detected in sputum or blood cultures. Based on the air-crescent sign observed on chest computed tomography and a diffuse pseudomembranous lesion on the airway epithelium that was observed via bronchoscopy along with positive serum Aspergillus antigen, a clinical diagnosis of invasive pulmonary aspergillosis (IPA) was made and liposomal amphotericin B was initiated. Three days later, the patient developed massive hemoptysis, and he died of respiratory failure. Later, aspergillus-like mycelia were observed in the pathology of bronchial biopsy, supporting the clinical diagnosis of IPA. Although the use of immune checkpoint inhibitors has been reported to be beneficial for patients with some infectious diseases, it does not seem to be the case for patients with other infectious diseases including our patient.

    DOI： 10.1016/j.rmcr.2022.101627

    PubMed

  • Dramatic response to alectinib in an ALK-positive LCNEC patient with a poor performance status: A case report Reviewed

    Respirology Case Reports   2021.8

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

  • Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post-operative recurrent pulmonary pleomorphic carcinoma Reviewed

    Respirology Case Reports   2021.3( ISSN：2051-3380 )

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

  • Myositis induced by durvalumab in a patient with non-small cell lung cancer: A case report Reviewed

    Thoracic Cancer   2020.12( ISSN：1759-7706 )

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

  • Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients Reviewed

    CANCER SCIENCE   2019.11( ISSN：1347-9032 )

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Coexistence of dementia with smear-positive pulmonary tuberculosis is associated with patient in-hospital mortality Reviewed

    Respiratory Investigation   2019.7( ISSN：2212-5353 )

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody Reviewed

    LUNG CANCER   2019.7( ISSN：0169-5002 )

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017 Reviewed

    LUNG CANCER   2019.5( ISSN：0169-5002 )

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer Reviewed

    Journal of Thoracic Disease   2019.5( ISSN：2072-1439 )

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer Reviewed

    Clinical Lung Cancer   2018.9( ISSN：1525-7304 )

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer Reviewed

    LUNG CANCER   2018.3( ISSN：0169-5002 )

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer Reviewed

    Respiratory Medicine Case Reports   2018.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene Reviewed

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   2017.12( ISSN：0368-2811 )

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • [Drunkenness caused by isoniazid in a tuberculosis patient with extrapulmonary lesions on hemodialysis: a case report].

    Masafumi Saiki, Takayuki Honda, Yusuke Sogami, Kazuhiro Fukasawa, Yoshihiro Miyashita, Kazumi Sano

    Kekkaku : [Tuberculosis]   88 ( 10 )   703 - 8   2013.10( ISSN：0022-9776 )

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    The patient was a 55-year-old man who had been on hemodialysis for 6 years for diabetic nephropathy. He was clinically diagnosed with pulmonary tuberculosis with extrapulmonary lesion after 3 years of chronic fever. His fever subsided immediately after the beginning of antituberculosis drug therapy and the antituberculosis drugs were discontinued 3 days after the initiation of the therapy. He experienced a sense of drunkenness when he received isoniazid, apparently not in association with any of the other antituberculosis drugs given. His blood trough concentration of isoniazid was nearly equal to the usual peak levels measured in patients with normal renal function. Isoniazid is often prescribed for patients with chronic renal failure without dose-reduction, because of its hepatic metabolism. But blood level of INH was found to accumulate at high levels in this patient. The high blood concentration of isoniazid in this patient with chronic renal failure may have elicited his neurological side effect.

    PubMed

▼display all

Presentations

  • 非小細胞肺癌における免疫チェックポイント阻害薬の治療開始時併用薬と有効性および免疫関連有害事象の関連

    日本肺癌学会総会  2024.11 

    　More details

    Language：Japanese   Presentation type：Oral presentation(general)  

  • PD-L1 TPS1-49%における化学療法+ICI,ipilimumab+nivolumab±化学療法の比較検討　TOPGAN2023-01

    日本肺癌学会総会  2024.11 

    　More details

    Language：Japanese   Presentation type：Oral presentation(general)  

  • 進行・再発非小細胞肺癌における免疫チェックポイント阻害薬の投与開始前検査と免疫関連有害事象の関連

    本間 健太, 齊木 雅史, 高橋 望, 古谷 智, 島村 壮, 大森 千咲, 大越 広貴, 星野 佑貴, 内田 賢典, 池村 辰之介, 副島 研造

    日本肺癌学会総会  2024.11 

    　More details

    Language：Japanese   Presentation type：Oral presentation(general)  

  • 根治的化学放射線療法とdurvalumab後に病状進行した局所進行非小細胞肺癌の次治療検討(TOPGAN2021-02)

    第63回日本肺癌学会学術集会  2022.12 

    　More details

    Event date： 2022.12

    Language：Japanese   Presentation type：Oral presentation(general)  

  • Pembrolizumab投与後早期にRamsay-Hunt症候群を発症した一例

    第 63 回日本肺癌学会学術集会  2022.12 

    　More details

    Event date： 2022.12

    Language：Japanese   Presentation type：Poster presentation  

  • 当院における高齢進行型小細胞肺癌患者に対するICI併用レジメンの後方視的検討

    第 63 回日本肺癌学会学術集会  2022.12 

    　More details

    Event date： 2022.12

    Language：Japanese   Presentation type：Oral presentation(general)  

▼display all

Guidance results

  • 2024

    Type：Achievement of hospital training physicians guidance

    Number of people receiving guidance ：30people 

  • 2022

    Type：Achievement of hospital training physicians guidance

    Number of people receiving guidance ：29people 

Other undergraduate student guidance

  • 2024

    Hospital clinical training - total time：200hours

Professional Memberships

  • 日本呼吸器内視鏡学会

  • 日本呼吸器学会